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Necrolytic migratory erythma (NME) is an obligatory paraneoplastic syndrome. Here we describe a woman admitted
to the dermatology ward with NME which was later found to be associated with glucagonoma, a slow-growing,
rare pancreatic neuroendocrine tumor. Even more rarely, the tumor was located in the pancreas head, while most
of such lesions are located in the distal pancreas. The diagnosis of this rare tumor requires an elevated serum
glucagon level and imaging confirming a pancreatic tumor. After surgical removal of the tumor, the patient’s
cutaneous and systemic features resolved. It is therefore imperative that clinicians recognize NME early in order to
make an accurate diagnosis and to provide treatment for this rare tumor.
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Necrolytic migratory erythema (NME) is a rare skin dis-
order which was first described by Becker et al. in 1942
[1]. Erythematous scaly lesions with centrifugal growth
characterize the clinical appearance of the disease. Peri-
neum, distal extremities, lower abdomen, and face are the
most commonly affected sites [2]. NME is an obligatory
paraneoplastic syndrome. Most of NME cases are associ-
ated with pancreatic neuroendocrine tumors (PNETs).
PNETs are rare neoplasms representing <5% of all pancre-
atic malignancies with an estimated incidence of 1 to 1.5
cases/100,000 [3] and are classified by the hormonal prod-
ucts that they produce. Glucagonomas, considered among
the rarest of PNETs, produce a well defined clinical syn-
drome characterized by NME, diabetes mellitus, glossitis,
anemia, and weight loss [4]. In this paper, we describe a
woman admitted to the dermatology ward with NME,
which was later found to be associated with glucagonoma
located at the head of the pancreas. We will describe
NME, the glucagonoma syndrome and how to recognize
and treat this rare tumor.* Correspondence: victorywu@163.com
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A 44-year-old woman presented with a 3-month history of
pruritic rash of the extremities and oral cavity. The rash
progressed to involve the groin, abdomen, axillae, and glu-
teal region. She was found to have well demarcated, ery-
thematous plaques in these regions. Tiny fragile vesicles
were observed at the margins of several plaques (Figure 1).
At this time, the patient was admitted to the dermatology
ward for further evaluation. The patient underwent aller-
gen patch testing, which was negative, and was treated
with topical steroids without clinical improvement. Skin
biopsy revealed psoriasiform acanthosis and abrupt necro-
sis of the upper layers of stratum; whereas the lower
half of epidermis appears viable, the detached necrolytic
portion appears pale with pyknotic nuclei. Perivascular
lymphocytic infiltration and scattered extravasated red
blood cells were present in the upper dermis.
Based on these findings, NME was considered. A gluca-
gon level was obtained and a contrast-enhanced CT scan
was conducted. Her level of serum glucagon was elevated
at 720 ng/L (normal values 40 to 130 ng/L) (Table 1) and
the scan revealed a 3-cm enhancing pancreatic head mass
(Figure 2). Thus, a referral to the hepatobiliary department
was made.
On admission, she had stable vital signs. Admission
laboratory measurements demonstrated hyperglycemia
(132 mg/dL, normal values 60 to 99 mg/dL) and anemia
(hemoglobin 11.4, normal values 12 to 16 g/dL). Serum. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Close-up view of well demarcated erythematous
plaques, with fragile vesicles on gluteal area.
Figure 2 Contrast-enhanced computed tomography scan of the
abdomen. A 3-cm nodular mass in the head of the pancreas was
seen. There was no evidence of metastases.
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docrine tumors, were elevated (243 ng/mL, normal
value <96 ng/mL), as were levels of glycosylated
hemoglobin (6.3%, normal value <5.7%) and the patient
was diagnosed with diabetes mellitus.
On hospital day 7, she underwent pancreaticoduode-
nectomy. Pathology confirmed a pancreatic neuroendo-
crine carcinoma with evidence of vascular and perineural
invasion, consistent with a diagnosis of a glucagonoma. In
the days following her operation, the patient was admitted
to the ICU, where she faced pancreatic fistula that
resolved with non-operative care. Her glucagon and glu-
cose blood levels dropped dramatically post-operatively
(Table 1). One week after the surgery, the patient's cutane-
ous lesions almost disappeared. Currently, more than
1 year post-operatively, there was no sign of cutaneous or
systemic disease.
Conclusions
Glucagonoma is a slow growing PNET, which is often
heralded by paraneoplastic phenomena. The key fea-
tures of the glucagonoma syndrome, a rare disorder
with an estimated incidence of 1 in 20 million [5], are
NME and diabetes mellitus [6]. Other common manifesta-
tions include weight loss, stomatitis, steatorrhea, diarrhea,
thromboembolic tendency, anemia, and neuropsychiatricTable 1 Laboratory values on the day of hospital
admission and hospital day 14 (post-operative day 7)






Glucose (mg/dL) 132 85 60–99
Glucagon (ng/L) 720 233 40–130
Chromogranin A (ng/mL) 243 87 <96
Glycosylated hemoglobin (%) 6.3 4.2 <5.7features [7]. Males and females are equally affected, with
an age peak presentation in the fifth decade of life [8].
The diagnosis of a glucagonoma requires an elevated
serum glucagon level and imaging confirming a pancreatic
tumor. Unfortunately, delays in diagnosis are common for
this slow growing tumor. It may proceed at least 1 year be-
fore a correct diagnosis is made [9]. At least half of pa-
tients will have metastatic disease when diagnosed [10].
Delays in diagnosis have been attributed to the extreme
rarity of the tumor, under-recognition of the dermato-
logic presentation, the difficulty making the diagnosis of
NME on biopsy, and the lack of specificity of the other
symptoms [11].
NME is the most specific feature of the syndrome, and is
the presenting symptom in approximately 70% of patients
[9]. The exact cause of NME remains unknown. Although
normalization of glucagon level by resection of the tumor
usually results in a rapid disappearance of the skin disorder
[12], elevation of serum glucagon levels alone cannot ex-
plain all of the skin findings, since hyperglucagonemia oc-
curring in other situations, such as trauma, burns, diabetic
ketoacidosis starvation and cirrhosis, does not lead to a
typical rash [13]. Hypoaminoacidemia or other nutritional
deficiencies, such as essential fatty acids or zinc, might also
contribute to the occurrence of NME because of the cuta-
neous histologic similarities between these deficiency states
and this syndrome [14,15]. The early recognition and
correct diagnosis of NME is important because it can
be the only and the first manifestation of the glucago-
noma syndrome. However, the correct diagnosis of
NME is challenging as the lesions of the NME may be
often misinterpreted as contact dermatitis, intertrigo,
inverse psoriasis, zinc deficiency, and other nutritional
deficiencies [7].
Diabetes mellitus is another common finding. Gluca-
gon has many important effects on glucose metabolism.
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and glycogen synthesis. Case studies suggest that 80%
of patients with glucagonomas will eventually develop
the disease [12].
Glucagonomas are typically distal pancreatic tumors,
generally large in size due to late detection, often meas-
uring between 4 and 10 cm [16]. However, the tumor in
our patient was located in the head of the pancreas,
which is uncommon for this disease. Moreover, the
tumor was detected in its early stage due to the prompt
and accurate diagnosis.
Contrast-enhanced CT is recommended to identify the
number and location of tumors. Somatostatin receptor
scintigraphy may be obtained if there is concern for dis-
tant disease [17]. The best and the most effective treat-
ment strategy should aim to lower serum glucagon levels.
A complete resection of the tumor is the best option be-
cause of its weak response to chemotherapy [14]. Patients
who underwent resection had significantly longer median
survival than patients who did not receive surgery, even
when diagnosed with later stages of disease [18].
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